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Abstract
With growing concerns that big data will only augment the problem of unreliable research, the Laboratory of Computational
Physiology at the Massachusetts Institute of Technology organized the Critical Data Conference in January 2014. Thought leaders
from academia, government, and industry across disciplines—including clinical medicine, computer science, public health,
informatics, biomedical research, health technology, statistics, and epidemiology—gathered and discussed the pitfalls and
challenges of big data in health care. The key message from the conference is that the value of large amounts of data hinges on
the ability of researchers to share data, methodologies, and findings in an open setting. If empirical value is to be from the analysis
of retrospective data, groups must continuously work together on similar problems to create more effective peer review. This
will lead to improvement in methodology and quality, with each iteration of analysis resulting in more reliability.
(JMIR Med Inform 2014;2(2):e22)   doi:10.2196/medinform.3447
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Introduction
Failure to store, analyze, and utilize the vast amount of data
generated during clinical care has restricted both quality of care
and advances in the practice of medicine. Other industries, such
as finance and energy, have already embraced data analytics
for the purpose of learning. While such innovations remain
relatively limited in the clinical domain, interest in “big data in
clinical care” has dramatically increased. This is due partly to
the widespread adoption of electronic medical record (EMR)
systems and partly to the growing awareness that better data
analytics are required to manage the complex enterprise of the
health care system. For the most part, however, the clinical
enterprise has not had to address the problems particular to “big
data” because it has not yet satisfactorily addressed more
fundamental data management issues. It is now becoming
apparent that we are on the cusp of a great transformation that
will incorporate data and data science integrally within the
health care domain. In addition to the necessary major digital
enhancements of the retrospective analyses that have variably
been in place, real time and predictive analytics will also become
ubiquitous core functionalities in the more firmly data-based
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environment of the (near) future. The initial Massachusetts
Institute of Technology (MIT) Critical Data Conference was
conceived and conducted to address the many data issues
involved in this important transformation [1,2].
Increasing interest in creating the clinical analog of “business
intelligence” has made evident the necessity of developing and
nurturing a clinical culture that can manage and translate
data-based findings, including those from “big data” studies.
Combining this improved secondary use of clinical data with a
data-driven approach to learning will enable this new culture
to close the clinical data feedback loop facilitating better and
more personalized care. Authors have noted several hallmarks
of “big data”: very large datasets, a large number of unrelated
and/or unstructured datasets, or high speed or low latency of
data creation [3,4]. The intensive care unit (ICU) provides a
potent example of a particularly data rich clinical domain with
the potential for both clinical and financial benefits if these large
amounts of data can be harnessed and systematically leveraged
into guiding practice. Thus, we use the term “Critical Data” to
refer to big data in the setting of the ICU.
This paper summarizes the lectures and group discussions that
took place during the recent Critical Data Conference at MIT,
Cambridge MA, on January 7, 2014. The conference was the
second part of a two-part event that brought together clinicians,
data scientists, statisticians and epidemiologists.
The event opened with a “data marathon” on January 3-5, 2014
(Figure 1), which brought together teams of data scientists and
clinicians to mine the Multiparameter Intelligent Monitoring in
Intensive Care (MIMIC) database (version II). MIMIC II is an
open-access database consisting of over 60,000 recorded ICU
stays from the adult intensive care units at the Beth Israel
Deaconess Medical Center (BIDMC) in Boston, MA [5]. Over
100 people participated in the two-day data marathon, and
posters of the projects were displayed at the Critical Data
Conference.
The Critical Data Conference on January 7 was an
approximately ten-hour program comprising two keynote
addresses (Jeffrey Drazen, MD and John Ioannidis, MD, PhD),
seven individual lectures, three panel discussions, and two poster
sessions (Figure 2). The overall conference theme was
meaningful secondary use of big data from critical care settings.
Materials from the conference (program, slides, and videos) are
available online at the MIT Critical Data conference site [6].
Figure 1. Presentation at the Critical Data Marathon. Photo credit: Andrew Zimolzak.
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Figure 2. Critical Data poster session. Photo credit: Andrew Zimolzak.
The Problem
In his keynote address, Jeffrey Drazen, MD, Editor-in-Chief of
the New England Journal of Medicine, noted that the number
of evidence-based recommendations built on randomized
controlled trials (RCTs), the current gold standard for data
quality, is insufficient to address the majority of clinical
decisions. Subsequently, clinicians are often left to practice
medicine “blindly.” Without the knowledge generation required
to capture the decisional factors involved in realistic clinical
scenarios, clinical decision making is often less data-driven than
determined by the “play of chance” buttressed by past
experience. Historically, a doctor took a history, performed a
physical examination and made a diagnosis based on what he
or she observed. As technology and medical theory progressed,
knowledge such as laboratory and imaging modalities helped
mitigate chance in the diagnosis of disease. Rote application of
existing knowledge is not enough, as physicians want to
establish causality. Until now this has been done with theories,
but moving forward, theories will be inadequate unless they are
confirmed, translated to practice, and systematically
disseminated in clinical practice.
This trial-and-error process continues today because data
generated from routine care is most often not captured and is
rarely disseminated for the purpose of improving population
health. Even in information-rich care settings like the ICU, the
knowledge necessary to mitigate the play of chance is lacking
[7,8]. As such, the ICU provides a fertile ground for potential
improvement. Specifically, Drazen suggested a potential role
for clinical data mining to answer questions that cannot be
answered using RCTs [9]. This approach would likely yield
benefits both more quickly and with fewer resources.
Drazen concluded with the question “At what point is data good
enough?” Documented associations may be strong but not
sufficiently “proven” to establish causality. Drazen drew a
comparison with experimental physicists who hone future
studies on the work of theorists as well as on prior experimental
results: biomedical informaticians can identify meaningful
associations that can then guide design of new RCTs where data
quality can be increased by controlling for potential confounders.
This will require cross-disciplinary collaboration of frontline
clinicians, medical staff, database engineers and biomedical
informaticians, in addition to strong partnerships with health
information system vendors in order to close the loop from
knowledge discovery during routine care to the real time
application of best care for populations.
Secondary Usage of Clinical Data
Charles Safran, MD, MS, Chief of the Division of Clinical
Computing at the BIDMC and Harvard Medical School, spoke
next, sharing the dream of evidence-based medicine (EBM):
the ideal situation in which quality evidence would exist to
guide clinicians through all the conundrums faced on a
near-daily basis (eg, which test to order, how to interpret the
test results, and what therapy to institute). For the last
half-century, prospective RCTs have been the gold standard in
EBM. Safran noted, as Drazen had, that such trials suffer from
a number of limitations including economic burdens and design
limitations. An RCT can only address a severely limited bundle
of particularly well-posed clinical questions. For many clinical
situations, it is either unethical or even impossible to proceed
with an RCT. Furthermore, the inclusion and exclusion criteria
often limit the generalizability of an RCT study and, given the
time it normally takes to run an RCT, it is very difficult for
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these studies to remain current with the rapidly evolving practice
of medicine.
Can another approach avoid at least some of the limitations of
RCTs? Safran suggested that retrospective observational studies
(ROS) utilizing EMR data are a promising avenue for generating
EBM. Digital records contain extensive clinical information
including medical history, diagnoses, medications, immunization
dates, allergies, radiology images, and laboratory and test results.
Consequently, routinely collected EMR data contains the rich,
continuous and time-sensitive information needed to support
clinical decision making and evidence generation [10]. However,
despite the many potential benefits, Safran pointed out that
secondary use of EMR data is still subject to limitations: EMR
data were not collected primarily for the purpose of evidence
generation and data analytics but for real-time and longitudinal
patient care [11]. As a result, EMR data are often poorly
structured, disorganized, unstandardized, and contaminated with
errors, artifacts, and missing values.
Safran echoed one of Drazen’s points by proposing that we
should combine the usage of prospective RCTs and ROS in
such a way that each complements the limitations of the other.
Furthermore, he suggested the possibility of incorporating
additional novel sources of data such as social media data, health
data from portable sensors, and genetic data. While there are
many barriers to establishing such a comprehensive framework,
a big data picture of clinical, genetic, and treatment variables
holds promise in revolutionizing diagnosis and treatment.
Connecting Patients, Providers, and
Payers
For John Halamka, MD, MS, the Chief Information Officer of
BIDMC, working with big data in hospital systems is hugely
challenging but at the same time holds tremendous promise in
providing more meaningful information to help clinicians treat
patients across the continuum of care. In his position, Halamka
has been tasked to aggregate data in novel ways in order to
provide better care for BIDMC’s patient population. One
opportunity for furthering “big data in health care” is to
normalize the data collected via their EMR system and store it
in large, centralized databases. In turn, analytic tools can then
be applied to identify and isolate the quality data reporting
measures required to participate as an Accountable Care
Organization (ACO) under the Affordable Care Act.
Halamka emphasized that building these large datasets does not
intrinsically provide value from the start, stating that “workflow
is disparate, the vocabulary is disparate, and the people are
disparate.” Therefore, the normalization of data and its
distillation into standard schemas are difficult due to
discrepancies across longitudinal data. Further, since each
vendor models concepts differently, there must be an emphasis
on developing a “least common denominator” concept map
across vendors’ offerings.
Nevertheless, through this normalization effort, doctors can
utilize “scorecards” to evaluate their own patient population
within and across the different payment models, such as Blue
Cross Blue Shield’s Alternative Quality Contact measures, the
Center for Medicare and Medicaid (CMS) Physician Quality
Reporting System measures, and the CMS ACO measures. In
addition, physicians can query this dataset to identify the most
effective treatment regimes. However, such queries do pose
privacy and security issues in the hospital setting, and these
risks are further complicated by hospital staff utilizing personal
mobile devices such as cell phones, laptops, and tablets.
Creating a Data-Driven Learning System
The problem posed to the first panel (Figure 3), comprising
Gari Clifford, PhD, Perren Cobb, MD, and Joseph Frassica,
MD, and moderated by Leo Anthony Celi, MD, MS, MPH, was
how to create a data-driven learning system in clinical practice
[8]. Privacy concerns were cited as the central barrier, as there
is a tradeoff between re-identification risk and the value of
sharing. Furthermore, recent work shows patients are reluctant
to share for certain purposes such as marketing, pharmaceutical,
and quality improvement measures, indicating a need for public
education about the benefits of data sharing and that shared data
can be utilized without being used for marketing and other
unwanted purposes [2].
There is also tension between intellectual property rights and
transparency. Resolution of this may require collaboration
between government, industry and academic institutions, as
seen with the US Critical Illness and Injury Trials Group [12].
There is also a risk that data sharing will make authors reluctant
to write audacious or unconventional papers (as did Reinhart
and Rogoff [13]), if data sharing puts such papers at perceived
higher risk of refutation (such as the refutation of Herndon et
al [14]).
Finally, the panel raised concerns about the high quantity but
perceived low quality of the data that is actually captured. While
there is hope that automatically captured data may be more
accurate than manually entered data, there is also some risk that
doing so will introduce additional noise, furthering the problem
of quantity over quality. This concern poses the challenge of
capturing more and higher quality data in order to promote
reproducibility. Panelists observed that multidisciplinary
conferences like the Critical Data Conference are especially
beneficial in this regard, as they provide an opportunity for
clinicians and data scientists to better understand the relation
between real-world activity and the data that such activity
generates.
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Figure 3. Data-driven learning system panel. Photo credit: Andrew Zimolzak.
Physician Culture as a Barrier to Spread
of Innovation
In the following panel moderated by critical care physician Leo
Anthony Celi, MD, MS, MPH, fellow intensivists Djillali
Annane, MD, PhD, Peter Clardy, MD and Taylor Thompson,
MD reflected on the barriers presented by the current clinician
culture toward the goal of data-driven innovation in medicine
(Figure 4). The panelists observed that historically, EBM was
perceived to be incompatible with well-established observational
trials and experience, perhaps instilling a residual degree of
resistance. Consequently, echoing Safran’s sentiments, it will
be increasingly important that “big data” is understood as a
complement to RCTs and (patho)physiologic studies.
Furthermore, condensing and filtering the vast quantity of data
to make it applicable at the bedside will be key to adoption. The
specific inclusion of clinicians during the design process will
help to deter the creation of tools that inundate staff with
extraneous information and burdensome extra tasks. Likewise
the incorporation of “big data” into medical education, in a way
that students and resident trainees will be able to understand its
importance in both everyday care and expediting research, is
vital.
While the panel agreed that more evidence is required to
determine whether big data can facilitate comparative
effectiveness research, it was acknowledged that it is necessary
to investigate this alternative since RCTs do not, and will not,
provide answers to an important fraction of the decisions
required on a daily basis. Scaling up RCTs to account for the
thousands of decisions each day is not feasible, so big data
approaches may provide the most effective way to fill these
gaps. For example, three groups currently leading clinical trials
research in the analysis of fluid resuscitation in critically ill
patients have collaborated to create a common database
architecture to allow for individual patient meta-analysis and
for these trials to be evaluated in aggregate by an external
monitoring committee.
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Figure 4. Physician culture panel. Photo credit: Andrew Zimolzak.
The Role of Industry in the Data
Revolution in Health Care
There is concern that industry continues to view data as a
potential source of revenue and would therefore be opposed to
providing open access to what they consider to be proprietary
data with business value. In the last panel discussion of the day,
moderated by Ambar Bhattacharyya, MBA of Bessem Venture
Partners, industry panelists Josh Gray, MBA of AthenaResearch,
Enakshi Singh, MS of SAP, and Omar Badawi, PharmD, MPH
of Philips Healthcare provided their insights on the topic.
They first addressed the issue of sharing databases freely, noting
that concerns associated with data ownership are not restricted
to industry. Similar problems and conflicts are observed among
most stakeholders in health care data ownership: patients,
hospitals, providers, payers, vendors, and academia. Generally
speaking, industrial data owners want to protect their data from
those who may use it competitively against them, share or sell
the data to derive direct clinical value, or profit from possible
insights. They also wish to avoid the overhead costs associated
with sharing. They are interested in allowing society to leverage
their data in order to make gains if, and only if, these other
interests remain unaffected.
The costs for responsibly sharing secondary clinical data are
not trivial. Although understanding the complexity of the data
presents a significant challenge, understanding the workflow
for entering data in the primary system is often even more
complicated, requiring extensive support. Therefore, sharing
secondary clinical data can be a costly initiative for industry,
lowering its priority as a business objective. These challenges
are further exacerbated when collaboration requires intellectual
property agreements. Lack of an accepted standard practice for
research agreements, coupled with an outdated patent system,
creates barriers to collaboration that are rarely overcome. Many
ideas for collaboration either take years to initiate or never come
to fruition, due to challenges with developing de novo legal
research agreements.
While industry and researchers are not philosophically opposed
to sharing data to ensure reproducibility, protections from the
aforementioned concerns are critical. Can the data be shared
without the risk of lost intellectual property? If not, the
incentives for innovation may be minimized. Who will bear the
costs for ensuring that the replicating team fully understands
the nuances of the data? Who will prevent competitors or others
with malicious intent from inappropriately labeling valid
research as “junk science”? Such underhanded interventions
could introduce confusion around valid earlier findings and
unfairly distract and denigrate the primary researchers.
Ultimately, there is a growing sense that data will become less
of a commodity over time if governments continue to support
the development and maintenance of open access research
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networks. As the scale and quality of these surpass those of
privately owned databases, society will benefit as the obstacles
to collaboration and the value of retaining private ownership
diminish.
The Unreasonable Effectiveness of Data
Peter Szolovits, PhD from the MIT Computer Science and
Artificial Intelligence Lab, highlighted how big data can often
trump good, but smaller, data. Researchers at Google have been
making a similar argument from a decade-long experience with
natural language processing, showing that for some important
tasks an order of magnitude growth in the size of a dataset leads
to improvements in performance that can overshadow
improvements in modeling technique [15]. They have also
argued that discarding rare events is a bad idea because although
these may be individually rare, they could prove to be significant
later when examined on a much larger scale.
In the clinical world, patient state depends on complex
pathophysiology dictated by genetic predispositions,
environmental exposures, treatments, and numerous other
factors. While, there are many potential ways to formulate
clinical outcomes into complex statistical models, it is often the
simple models that give the best, and most interpretable, results.
Some clinicians and epidemiologists have already used large
sources of observational data to improve clinical practice,
especially in identifying drug side-effects, for example, for
rosiglitazone [16], and rofecoxib [17]. Cox proportional hazard,
naïve Bayes, linear and logistic regression, and similar models
can use aggregated variables to summarize dynamic variation
without adding additional complexity.
The Story of MIMIC: Open-Access Critical
Care Data
Since researchers who seek to create new clinical knowledge
and tools are dependent upon the availability of relevant data,
restricting access to data introduces barriers that stifle research
progress. This simple principle has been at the heart of the
research of Roger Mark, MD, PhD since the 1980s, a time when
his work was focused on developing real-time arrhythmia
analysis tools for use in patient monitoring.
Like today, the norm for researchers in the 1980s was to
privately maintain closed databases for their own benefit. So
when Mark’s team needed data, they began the painstaking
work of creating their own resource, collecting
electrocardiograms from patients at Boston’s BIDMC and in
the process, adding over 100,000 annotations. Breaking from
tradition, they openly shared the dataset, reasoning that the more
people who analyzed it, the better the overall understanding of
arrhythmias would become. This dataset become known as the
MIT-Beth Israel Hospital (MIT-BIH) Arrhythmia Database
[18].
The consequences were far-reaching. Not only did the MIT-BIH
Database stimulate research interest, it generated beneficial
competition and became a shared resource for evaluating
algorithms. Researchers competed to see whose work performed
best on the standard data, eventually leading to the database
becoming part of a federal requirement for evaluation of
commercial algorithms. This success led the team to develop
further resources unique in their openness, including PhysioNet,
a platform for open physiologic data, and MIMIC II, a rich
database of critical care data.
PhysioNet has over 50,000 registered users in over 120 countries
and international recognition for accelerating the pace of
discovery [19]. Mark attributes much of PhysioNet’s success
to the progressive mindset of the participating collaborators.
Success has required not only funding, but also a collaborative
approach among partnering clinicians, researchers, hospital
technologists, and local ethics committees. Participation of
commercial partners was also required, and obtained, in order
to decrypt the proprietary data formats output by their
monitoring systems.
Reproducibility of research and open data are increasingly
getting the attention they deserve, but changing practice requires
support at all levels [8]. For open technology to be embraced,
funders must recognize the added value from a robust database
infrastructure and allocate funds accordingly. Researchers too
must embrace open approaches that perhaps challenge some of
the underlying career reward systems. With changing attitudes,
and by engaging the creative energy of the worldwide research
community, Mark’s hope is that MIMIC will become a
multinational resource leading to the generation of new
knowledge and new tools.
Opportunities and Challenges in
Wearable Sensor Datasets
The ability to create and capture data is exploding and offers
huge potential for health organizations around the world to save
both lives and scarce resources. Yadid Ayzenberg, PhD
discussed the “Opportunities and Challenges in Wearable Sensor
Data” in his talk, focusing on how the combination of wearable
technology and the near ubiquitous access to mobile phones
have the potential to address some of the challenges in health
care. Examples include the works of Poh et al [20] and Sano
and Picard [21], which used a wrist-worn electrodermal activity
and accelerometry biosensor for detection of convulsive seizures
and sleep stages.
Wearable technologies provide a way to transition from a
traditional aperiodic “snapshot” monitoring approach to a
continuous and longitudinal monitoring paradigm, increase
patients’ engagement in their care, and facilitate doctor-patient
interactions. Already massive amounts of personal health data
are being generated through consumer devices such as mobile
phones and wristbands that monitor sleeping patterns, exercise,
stress, calorie consumption and more. In most instances,
however, the data are stored on a per-device basis, and there
are unsolved issues concerning data management, ownership,
privacy, and misuse. The noise and artifacts in the data measured
by wearable sensors also present an important challenge. New
analytic methods that transform “dirty data” into good quality
data are needed.
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Big Data, Genomics, and Public Health
According to Winston Hide, PhD, the promise of a new
economy based on data-driven discovery and decision-making
is also motivating his own field of genomics. Advances in
genome sequencing technology will allow the cost of sequencing
a genome to be less than $100 in the near future. Consequently,
it is estimated that by 2015, one million genomes will be
digitally available with high expectations for public health
benefits. However, Hide cautions that there is still a “genome
variants” problem to be solved. This was exemplified by the
case of Kira Peikoff who was predicted to have a 20% above
average risk of developing psoriasis by one commercial
sequencing product, while predicted to have a 2% below average
risk for the same condition by another [22].
Variations in the reporting of genomic characteristics have two
potential root causes. First, there is a sampling problem caused
by the use of different sequencing technologies, which
introduces errors in evaluating genome assembly. Second, there
is an interpretation problem in defining the role of genes in
disease which compromises the prediction of clinical outcomes
as determined by the single-nucleotide polymorphism analysis
tools.
The availability of millions of genomes will allow completion
of the catalogue of genes associated with a particular disease
in genome-wide association studies. However, Hide maintains
that finding clear drug targets requires the creation of an
evolving catalogue of functions which would interpret complex
gene pathways [23], and the selection of cohorts that would not
only depend on ethnicity (the classic phenotype), but also on
physiological and even molecular differences.
The application of genomic tests to public health will contribute
to the transformation of physicians into data-centric specialists
and pave the way for “precision medicine” [24]. This
challenging way of delivering health care calls for new strategies
and tactics for translating research into clinical practice. These
will likely include the creation of open-access genomic and
clinical databases, use of a common scientific language [25]
and (open) data access tools. Regulatory bodies, such as the
Food and Drug Administration, will have a role in guaranteeing
the standardization and reliability of diagnostics based on
genetic tests. These tools must guarantee the reproducibility [8]
of discovered genome signals and contribute to the improvement
of online platforms that map genetic features to diseases and
their treatment (eg, Cancer Genome Atlas; PharmGKB).
The Pitfalls and Potential of Big Data in
Health Care
Proponents of big data have made grandiose claims of expanding
human knowledge by orders of magnitude through empirical
analysis and data mining, but as Stanford professor John
Ioannidis, MD, PhD says, “with big data comes big problems”.
Ioannidis discussed the darker side of data analysis, in which
bias has led a large proportion of published medical science to
come to the wrong conclusion. Author of the most downloaded
paper in PLOS Medicine, “Why Most Published Research
Findings Are False” [26], Ioannidis argued that most statistically
significant results are likely to be false positives. For example,
using the national drug and cancer registry database of Sweden,
Ioannidis and colleagues found that almost one third of the 560
medications evaluated in isolation were associated with a higher
cancer risk.
As Ioannidis highlights, the issue is not in the quantity of data
we have. Increasing sample sizes is a huge boon to the medical
field. The issue resides in a lack of transparency. When he
reviews a paper published in a journal on a new dataset, his
thoughts immediately drift to those studies that were not
published. This is quantified in the so-called “vibration of
effects”, where depending on the confounding variables for
which adjustments are made, completely opposite conclusions
can be drawn. For vitamin E, for example, adjusting for a certain
subset of confounders led to the conclusion that it increases the
relative risk of mortality, whereas adjusting for another equally
plausible set of confounders gave the opposite result, that is, a
reduction in mortality risk. This may explain why 90% of effects
in RCTs were lower in subsequent published trials [27].
Comparative Effectiveness Using Big
Data
Limitations aside for now, ROS do provide an opportunity to
conduct comparative effectiveness studies on research questions
that would be unlikely to be examined by an RCT, or would be
inherently biased if an RCT were conducted. The illustrative
example presented by Una-May O’Reilly, PhD was the question
of the potential benefit of diuretic use to accelerate removal of
fluids given during resuscitation in ICU patients who have
recovered from sepsis. Retrospective analysis would be easily
marred by “selection bias”. In fact, if patients are allocated (not
randomized) to two groups, treatment and non-treatment, it is
very likely that the allocation would be done on the basis of
patient condition and biased by clinical severity resulting in
unreliable results.
In a ROS, the data consists of a series of days during which the
treatment was administered (D+) or not (D-). Because these
decisions were being made on a daily basis, it is even harder to
capture the covariance structure. O’Reilly refers to this as the
“Non-Decision Day Dilemma”. In order to deal with this, the
covariance structure has to account for time-varying information
with respect to a specific day. It is easy to take the treatment
day as a reference and align all patients who received treatments
with respect to this event (D+). For non-treated patients, aligning
time-series is more complicated as every day is essentially a
“non-decision day”. Considering every single day would result
in a widely unbalanced dataset where the length-of-stay
influences the individual contribution of each patient. To account
for this, it is possible to randomly sample N negative days (D*-)
and pair them up with the positive instances (D+) based on a
statistical similarity criterion with respect to the time from
admission. This is achieved by defining a propensity score for
each patient for every day during their ICU stay. The propensity
score thus enables appropriate cohort matching such that
comparative effectiveness can be appropriately assessed.
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This modest example illustrates the sort of robust and reliable
statistical technique that evidence-based medicine requires. It
can reduce sample noise and improve the reliability of
conclusions, and it leads toward methodology standardization
across studies. Beyond these local improvements, meta-studies
will also be a requirement to validate any local finding. These
are only possible with data sharing and open data initiatives
such as the MIMIC-II initiative. One strength of this database
is the dual culture and scientific activity it generates because
data science can only fully benefit from collaboration between
data scientists and domain experts (in this case, intensivist
physicians).
Conclusions
Although the future of “big data” in health care remains unclear,
its role will be undeniably important. This conference was
effective in collating the broad range of perspectives on the
many challenges facing EBM in the 21st Century. As several
speakers suggested, one possible opportunity is to adopt a
pragmatic approach to EBM, combining RCT and ROS. This
combination may employ ROSs to fill the gaps where it is
impractical, unlikely or impossible to conduct a RCT or to drive
hypothesis generation for further RCT analysis.
It is also crucial to acknowledge that any ROS requires a
multidisciplinary approach, integrating clinical knowledge with
a broad range of data analytic skills ranging from biostatistics,
machine learning, and signal processing to data mining.
Encouraging a change in physician culture can likely be
accomplished through updating education programs as well as
by creating centers for excellence that can showcase the impact
of ROS to the broader medical fraternity. These centers for
excellence should host open, transparent, easily accessible data
warehouses, which will facilitate study reproducibility and allow
for a new wave of collaborative learning. Only by understanding
the potential biases of any analysis, and fostering a system of
normative data sharing, will the medical community be able to
gain reliable knowledge from data, and produce research
findings that do not turn out to be false.
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